Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash from Investing Activities: 2024-2025

Historic Cash from Investing Activities for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $40.0 million.

  • Zenas BioPharma's Cash from Investing Activities rose 249.64% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.3 million, marking a year-over-year change of. This contributed to the annual value of -$30.6 million for FY2024, which is 179617.65% down from last year.
  • Per Zenas BioPharma's latest filing, its Cash from Investing Activities stood at $40.0 million for Q3 2025, which was up 135.66% from -$112.3 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Cash from Investing Activities peaked at $40.0 million during Q3 2025, and registered a low of -$112.3 million during Q2 2025.
  • Its 2-year average for Cash from Investing Activities is -$27.0 million, with a median of -$3.7 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Zenas BioPharma's Cash from Investing Activities was 249.64% (2025), while the steepest drop was 392,054.55% (2025).
  • Zenas BioPharma's Cash from Investing Activities (Quarterly) stood at -$3.7 million in 2024, then skyrocketed by 249.64% to $40.0 million in 2025.
  • Its Cash from Investing Activities stands at $40.0 million for Q3 2025, versus -$112.3 million for Q2 2025 and -$86.3 million for Q1 2025.